Cellular Biomedicine: International Conference on Translational Medicine 2015 (Cellular Biomedicine Group) - Nov 5, 2015 - “Summary of the Phase IIa Trial”; “Toxicity: No severe toxicity: 2/10 patient experienced Grade 3 toxicity, No CRS or TLS development”; “Efficacy: ORR=80.0% 8/10 had clinical response: 5/10 (50.0%) CR ≥ 4 months, 3/5 CR ≥ 5 months, 3/10 (30.0%) PR≥ 2 months, 2/3 PR 6-11 months”; “Exploratory Observations”; “An inverse correlation between the molecule levels of the CAR gene and disease recurrence or progression was observed”; “The lesions in some special organ sites such as spleen and testicle were refractory to CART-20 treatment”
P2a data • Non-Hodgkin's Lymphoma • Oncology
|